Luminopia

Focus: Luminopia is a Series A biotech focused on binocular amblyopia therapy, a novel approach to treating lazy eye in the ophthalmology space. The company is early-stage and pre-revenue.

Ophthalmology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

SERIES A

Open Jobs

About Luminopia

AI assessmentNot Hiring

No open roles listed right now. Follow Luminopia to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Luminopia One

Amblyopia

N/A

Clinical Trials (1)

NCT02782117Luminopia One Pilot Study

N/A

Help build intelligence for Luminopia

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a Series A company with a focused pipeline in an underserved ophthalmology indication (amblyopia).
Potential to shape culture and processes at an early stage before organizational inertia sets in.
Working on a potentially transformative therapeutic approach rather than crowded therapeutic areas.

Watch Out For

No active job openings currently listed, suggesting limited near-term hiring or organizational scaling.
Pre-revenue status with limited financial visibility means high execution and fundraising risk ahead.
Early-stage companies have higher failure rates and career trajectory uncertainty compared to funded peers.

Generated by Claude from Luminopia's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

N/A this is an observational study of Standard of Care

Amblyopia

N/A

Clinical Trials (1)

NCT06429280Clinical Data Registry of Amblyopia Patients on Luminopia Treatment

N/A

Luminopia One

Amblyopia

N/A

Clinical Trials (1)

NCT03608150Luminopia One Amblyopia Vision Improvement Study

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo